Royalty Pharma Reports 2026 Revenue of $690.1 Million, EPS of $0.32
Revenue rose 13.3% year over year, while net income attributable to the company fell 49.1% to $144.68 million and diluted EPS declined 51.5%.
Royalty Pharma reported revenue of $690.1 million for the 2026 period, up 13.3% from the prior-year period, while net income attributable to the company fell 49.1% to $144.68 million and diluted EPS declined 51.5% to $0.32.Financial Highlights¹ Reported as “Total income and other revenues”. ² Repor…